Andersen, L.B.; Mahler, M.S.K.; Andersen, R.F.; Jensen, L.H.; Raunkilde, L.
The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab. Cancers 2022, 14, 4598.
https://doi.org/10.3390/cancers14194598
AMA Style
Andersen LB, Mahler MSK, Andersen RF, Jensen LH, Raunkilde L.
The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab. Cancers. 2022; 14(19):4598.
https://doi.org/10.3390/cancers14194598
Chicago/Turabian Style
Andersen, Line Bechsgaard, Marit Sofie Kjær Mahler, Rikke Fredslund Andersen, Lars Henrik Jensen, and Louise Raunkilde.
2022. "The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab" Cancers 14, no. 19: 4598.
https://doi.org/10.3390/cancers14194598
APA Style
Andersen, L. B., Mahler, M. S. K., Andersen, R. F., Jensen, L. H., & Raunkilde, L.
(2022). The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab. Cancers, 14(19), 4598.
https://doi.org/10.3390/cancers14194598